UK-based pharmaceutical giant GlaxoSmithKline has announced, alongside AstraZeneca and the University of Manchester, UK, a collaboration to work on inflammation research and translational medicine.
The Manchester Collaborative Centre for Inflammation Research (MCCIR), established with an initial investment of £5m, will bring together scientists from the pharmaceutical industry and academia to work collaboratively.
The ultimate goal of the centre is to translate findings into new and improved treatments, with such advances potentially benefitting those suffering from diseases associated with chronic inflammation, including asthma, chronic obstructive pulmonary disease and rheumatoid arthritis.
The MCCIR will be formally opened later this year at the University of Manchester, with University of Manchester vice president and dean of the Faculty of Medical and Human Sciences, Professor Ian Jacobs, adding, “The University of Manchester welcomes greatly this opportunity to ensure that some of its fundamental biomedical research will become more closely aligned with the need to develop new therapies for inflammatory diseases.”
